Biomarker

Interviews with clusters

Biomarkers mainly supported by standard cluster tools, very little cluster specific efforts. Clusters may play a role in regional agenda setting promoting biomarkers if BiC can deliver USP’s and trans-national complimentary tools.

Experience and cluster support to biomarker development

  • Cluster support to biomarker development: Policy influencing, regulatory guidance, overview of competencies, market research, match making, connecting academia and industry, internationalization support, marketing, networking, identifying project funding sources,
  • Cluster priority: Most do not work directly with biomarkers. Only Biopeople has biomarkers as a specific topic they work on.

Conclusion: Biomarkers mainly supported by standard cluster tools, very little cluster specific efforts. Clusters may play a role in regional agenda setting promoting biomarkers if BiC can deliver USP’s and trans-national complimentary tools.

Milestones in biomarker commercial development

  • Identify market need and market size and understand reimbursement system
  • Find a customer to finance development, validation and market awareness.
  • Getting access to the clinics for testing
  • Validation the top priority.
  • Most important is the Phase III in clinical trials
  • Be aware of the high costs of marketing – more expensive than the development phase
  • Preparing a business model and business plan
  • Do not forget the regulatory part.
  • Get the marketing and sales force in place

Conclusion: What can a trans-national platform assist with? Maybe (1) market and reimbursement insight (2) match making between academia and paying customer (3) trans-national access to courses and training (4) trans-national access to competencies

Economy and reimbursement

  • Despite CE regulation, each country has own additional rules
  • High cost of biomarkers not a hindrance if benefits are even larger

Conclusion: A trans-national platform may facilitate access to knowledge on different reimbursement systems. Market analysis crucial to argue for the relevance of high biomarker costs

Translation to clinical setting

  • Early involvement of industry important

 

CloseClose
What are you looking for?
By using this website, you agree to the use of cookies to give you the best user experience.
Find additional information at Cookies
Ok